3rd Human Abuse Liability & Abuse-Deterrent Formulations – 3rd Human Abuse Liability & Abuse-Deterrent Formulations

Featured Speakers



In spring 2016, the FDA released the long-awaited draft guidelines that brought generic drug manufacturers into the abuse-deterrent formulations market.  This new regulatory framework comes at a time when public concerns about abuse of prescription opioids has never been higher — and yet obstacles to market uptake remain due to payer and prescriber hesitancy.

This period of upheaval is why you cannot afford to miss the 3rd Human Abuse Liability & Abuse-Deterrent Formulations conference — the largest and most specifically focused educational event devoted to improving trial designs, engineering less abuse-prone molecules and delivery systems, and tracking the performance and market uptake of opioids in order to document the success of abuse-deterrent methods.  Over the past three years this event has brought more than 200 industry leaders together, and this year is going to have our most in-depth educational and networking opportunities yet!

Top Five Reasons to Attend

  1. Insight on the latest regulatory guidelines for branded and generic opioids
  2. Lessons learned from FDA advisory committee meetings
  3. State-of-the-art reviews of prodrug technologies, agonist/antagonist formulations and novel delivery mechanisms
  4. Techniques to find and document the data showing the uptake and abuse rate of specific opioid types
  5. A way forward to make the case to payers, patients and physicians that your opioids are truly less of an abuse risk

Who Should Attend

This event is designed for pharmaceutical, biotech and medical device professionals responsible for:

  • Regulatory Affairs/Intelligence
  • Epidemiology/Pharmacoepidemiology
  • Clinical Development/Operations/Affairs/Programs
  • Risk Management/REMS
  • Toxicology
  • Drug Safety
  • Pharmacology/Clinical Pharmacology/Safety Pharmacology
  • CNS/Neuroscience
  • Medical Affairs
  • Scientific Affairs
  • Formulations
  • Analytical Development
  • R&D
  • Pharmacovigilance
  • Pharmacoeconomics/Health Economics/Outcomes Research/HEOR
  • Commercial Affairs
  • Legal Affairs/Legal Counsel

This event is also of interest to:

  • CROs
  • Toxicology Specialists
  • Drug Abuse Registry/Surveillance Specialists
  • REMS/Pharmacovigilance Specialists
  • Formulation Service Providers
  • Pharmacokinetics Service Providers
  • Abuse Liability Service Providers
  • Regulatory Specialists
  • IP Service Providers